(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback